The Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS.
The scope of the multiple sclerosis therapeutics market includes drug class, route of administration, distribution channel, and region. The market for multiple sclerosis therapeutics is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the multiple sclerosis therapeutics market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Multiple Sclerosis Therapeutics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Multiple Sclerosis Therapeutics Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Market Insights
Growing Prevalence of Multiple Sclerosis
Multiple sclerosis is a chronic disease that affects the brain, spinal cord, and optic nerves. The symptoms of multiple sclerosis include weakness, anxiety, abnormality of taste, reduced sensation, and blurred vision or vision loss. Some of the other signs are constipation, muscle stiffness, depression, thinking problems, and urinary problems.
Studies suggest that there is an increase in prevalence of multiple sclerosis across the globe. For instance, as per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were living with MS in the US. In 2010, estimated prevalence of the disease was 309 cases per 100,000 people, that is, there were 727,344 adults suffering from MS. Additionally, as per the Government of Canada, (2014–2015 estimates) over 77,000 Canadians are living with multiple sclerosis of which 3/4th are women.
Further, the Multiple Sclerosis Society estimated that about 110,000 people were suffering from the condition in the UK in 2018. It also mentioned that MS is more than twice prevalent in females than males. The number of new patients diagnosed per year is also increasing; it increased from 5,000 in 2017 to 6,700 in 2018.
Therefore, growing prevalence of multiple sclerosis is driving the multiple sclerosis therapeutics market.
Drug Class Based Insights
Based on multiple sclerosis therapeutics drug class, the multiple sclerosis therapeutics market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in MS treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.
Route of Administration Based Insights
In terms of route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.
Distribution Channel Based Insights
Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.
COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID 19 has been established. Patients with severe health conditions, such as neurological diseases and others; are witnessing delays in such chronic disease treatment. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to open during the lock down. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the outbreak of COVID-19 pandemic.
Product launches and expansion strategies are commonly adopted by companies to expand their footprint worldwide and meet the growing demand. These strategies are commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the Multiple Sclerosis Therapeutics Market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.
Multiple Sclerosis Therapeutics Market Regional Insights
The regional trends and factors influencing the Multiple Sclerosis Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Multiple Sclerosis Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

- Get the Regional Specific Data for Multiple Sclerosis Therapeutics Market
Multiple Sclerosis Therapeutics Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 24.03 Billion |
Market Size by 2027 | US$ 39.22 Billion |
Global CAGR (2019 - 2027) | 6.5% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Drug Class
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Multiple Sclerosis Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics
The Multiple Sclerosis Therapeutics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Multiple Sclerosis Therapeutics Market are:
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
Disclaimer: The companies listed above are not ranked in any particular order.

- Get the Multiple Sclerosis Therapeutics Market top key players overview
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
- South America (SAM)
- Brazil
- Argentina
- Rest of South America
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
- Biogen
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















The List of Companies - Multiple Sclerosis Therapeutics Market
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
- Biogen


